CD274 and neoplasm: On the other hand, clinical trials with atezolizumab have adopted the SP142 PD-L1 assay to quantify PD-L1+ immune cells, and PD-L1 positivity was determined by the presence of the discernible PD-L1 staining of any intensity covering  ≥1% of tumor-infiltrating immune cells in the tumor area [1,4,5].